In Agilent Technologies, Inc. v. Sytnhego Corp., the US Court of Appeals for the Federal Circuit affirmed final written decisions by the Patent and Trademark Appeal Board (PTAB) finding that all challenged... Read more »
Amgen’s $28 billion purchase of Horizon Therapeutics can now proceed following a settlement with the Federal Trade Commission, but with safeguards designed to preserve competition in two rare diseases where Horizon’s drugs... Read more »